Vermillion & White Wealth Management Group LLC Acquires New Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

Vermillion & White Wealth Management Group LLC acquired a new stake in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 3,500 shares of the biotechnology company’s stock, valued at approximately $31,000.

A number of other hedge funds have also recently modified their holdings of AUPH. SBI Securities Co. Ltd. purchased a new stake in shares of Aurinia Pharmaceuticals in the fourth quarter valued at about $25,000. Tower Research Capital LLC TRC boosted its stake in Aurinia Pharmaceuticals by 368.5% during the fourth quarter. Tower Research Capital LLC TRC now owns 3,350 shares of the biotechnology company’s stock worth $30,000 after buying an additional 2,635 shares during the period. Natixis purchased a new position in Aurinia Pharmaceuticals during the fourth quarter worth about $49,000. Blue Trust Inc. boosted its stake in Aurinia Pharmaceuticals by 3,041.4% during the fourth quarter. Blue Trust Inc. now owns 6,377 shares of the biotechnology company’s stock worth $57,000 after buying an additional 6,174 shares during the period. Finally, Susquehanna Fundamental Investments LLC purchased a new position in Aurinia Pharmaceuticals during the fourth quarter worth about $90,000. Hedge funds and other institutional investors own 36.83% of the company’s stock.

Wall Street Analyst Weigh In

Separately, StockNews.com raised shares of Aurinia Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Thursday, March 27th.

Insider Transactions at Aurinia Pharmaceuticals

In other news, insider Greg Keenan sold 12,239 shares of the stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $8.00, for a total transaction of $97,912.00. Following the sale, the insider now owns 161,789 shares of the company’s stock, valued at approximately $1,294,312. This represents a 7.03% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Joseph M. Miller sold 61,859 shares of the stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $8.00, for a total transaction of $494,872.00. Following the sale, the chief financial officer now directly owns 633,515 shares in the company, valued at $5,068,120. This represents a 8.90% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 343,898 shares of company stock valued at $2,753,094. 4.30% of the stock is currently owned by corporate insiders.

Aurinia Pharmaceuticals Trading Up 0.5%

Shares of AUPH stock opened at $8.19 on Monday. The company has a debt-to-equity ratio of 0.17, a current ratio of 5.60 and a quick ratio of 5.11. The firm has a market cap of $1.11 billion, a PE ratio of -54.60 and a beta of 1.16. The company has a 50-day moving average of $8.02 and a two-hundred day moving average of $8.25. Aurinia Pharmaceuticals Inc. has a 1-year low of $5.11 and a 1-year high of $10.67.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last announced its earnings results on Monday, May 12th. The biotechnology company reported $0.16 earnings per share for the quarter, topping the consensus estimate of $0.08 by $0.08. The company had revenue of $62.47 million during the quarter, compared to analyst estimates of $61.06 million. Aurinia Pharmaceuticals had a negative net margin of 10.23% and a negative return on equity of 4.41%. On average, analysts predict that Aurinia Pharmaceuticals Inc. will post 0.11 EPS for the current year.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.